Sanara MedTech Inc. (SMTI) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
1200 Summit Avenue
Fort Worth, TX 76102
United States of America (the)
Phone
817 529 2300
Website
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
141
First IPO Date
April 07, 1994
| Name | Title | Pay | Year Born |
| Suresh V. Muppalla | President & Chief Executive Officer of THP | 872,006 | N/A |
| Seth Yon | President, Chief Executive Officer & Director | 2.14M | 1975 |
| Ronald T. Nixon | Executive Chairman | 322,994 | 1956 |
| Elizabeth Taylor | Chief Financial Officer | 458,926 | 1976 |
| Jacob A. Waldrop | Chief Operating Officer | 561,600 | 1982 |
| Bill Fitzgerald | Chief Compliance Officer | 0 | N/A |
| Tricia Matteson | Vice President of Marketing | 0 | N/A |
| Nina Bionda | Chief R&D Officer | 0 | N/A |
| Tyler Palmer | Chief Corporate Development & Strategy Officer | 0 | N/A |
| Ashley Mackey | Principal Accounting Officer | 0 | 1986 |
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.